Halozyme Long Term Debt Total vs Deferred Long Term Liab Analysis

HALO Stock

USD 48.20 0.27 0.56%

Halozyme Therapeutics financial indicator trend analysis is much more than just examining Halozyme Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Halozyme Therapeutics is a good investment. Please check the relationship between Halozyme Therapeutics Long Term Debt Total and its Deferred Long Term Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.

Long Term Debt Total vs Deferred Long Term Liab

Long Term Debt Total vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Halozyme Therapeutics Long Term Debt Total account and Deferred Long Term Liab. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Halozyme Therapeutics' Long Term Debt Total and Deferred Long Term Liab is -0.62. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Halozyme Therapeutics, assuming nothing else is changed. The correlation between historical values of Halozyme Therapeutics' Long Term Debt Total and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Halozyme Therapeutics are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Long Term Debt Total i.e., Halozyme Therapeutics' Long Term Debt Total and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

-0.62

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Long Term Debt Total

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Halozyme Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Halozyme Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.At this time, Halozyme Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 29th of November 2024, Tax Provision is likely to grow to about 70.1 M, while Sales General And Administrative To Revenue is likely to drop 0.44.

	2021	2022	2023	2024 (projected)
Gross Profit	361.9M	520.8M	636.9M	668.7M
Total Revenue	443.3M	660.1M	829.3M	870.7M

Gross Profit Total Revenue

Halozyme Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Accounts Payable	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Inventory	Other Current Assets	Property Plant And Equipment Gross	Property Plant Equipment	Current Deferred Revenue	Net Receivables
Total Assets		0.91	0.26	0.41	0.98	0.69	0.63	0.49	0.35	0.33	-0.52	0.99	0.88	0.27	0.99	0.79	0.94	0.94	0.83	0.76	0.96	0.74	0.95	0.93	-0.74	0.97
Other Current Liab	0.91		0.16	0.34	0.89	0.48	0.53	0.34	0.4	0.36	-0.35	0.91	0.74	0.32	0.89	0.86	0.92	0.9	0.7	0.49	0.88	0.51	0.91	0.92	-0.73	0.9
Total Current Liabilities	0.26	0.16		0.58	0.17	-0.15	0.53	0.51	0.41	0.46	0.32	0.2	0.48	0.41	0.21	0.02	0.11	0.07	0.5	0.14	0.33	0.56	0.1	0.1	-0.06	0.29
Total Stockholder Equity	0.41	0.34	0.58		0.25	0.01	0.62	0.79	0.49	0.54	0.29	0.29	0.66	0.51	0.29	0.22	0.17	0.17	0.53	0.39	0.28	0.5	0.18	0.14	0.0	0.29
Net Debt	0.98	0.89	0.17	0.25		0.75	0.5	0.38	0.25	0.22	-0.64	0.99	0.81	0.16	1.0	0.75	0.95	0.96	0.77	0.77	0.97	0.72	0.97	0.95	-0.8	0.98
Retained Earnings	0.69	0.48	-0.15	0.01	0.75		0.19	0.02	-0.3	-0.33	-0.95	0.72	0.41	-0.39	0.74	0.51	0.73	0.79	0.5	0.65	0.67	0.39	0.76	0.73	-0.63	0.7
Cash	0.63	0.53	0.53	0.62	0.5	0.19		0.65	0.55	0.6	0.01	0.57	0.69	0.55	0.57	0.61	0.48	0.48	0.82	0.39	0.49	0.55	0.47	0.43	-0.08	0.56
Cash And Short Term Investments	0.49	0.34	0.51	0.79	0.38	0.02	0.65		0.59	0.65	0.22	0.41	0.83	0.59	0.42	0.15	0.17	0.18	0.59	0.67	0.35	0.76	0.21	0.15	-0.08	0.34
Common Stock Total Equity	0.35	0.4	0.41	0.49	0.25	-0.3	0.55	0.59		0.98	0.45	0.3	0.53	0.98	0.28	0.33	0.21	0.18	0.45	0.24	0.29	0.45	0.21	0.2	-0.04	0.28
Common Stock Shares Outstanding	0.33	0.36	0.46	0.54	0.22	-0.33	0.6	0.65	0.98		0.49	0.28	0.55	0.99	0.26	0.29	0.16	0.13	0.48	0.27	0.26	0.5	0.16	0.14	0.06	0.25
Other Stockholder Equity	-0.52	-0.35	0.32	0.29	-0.64	-0.95	0.01	0.22	0.45	0.49		-0.59	-0.18	0.54	-0.6	-0.41	-0.64	-0.69	-0.32	-0.5	-0.55	-0.21	-0.66	-0.64	0.59	-0.58
Total Liab	0.99	0.91	0.2	0.29	0.99	0.72	0.57	0.41	0.3	0.28	-0.59		0.83	0.22	1.0	0.79	0.96	0.96	0.8	0.74	0.97	0.71	0.97	0.95	-0.77	0.98
Total Current Assets	0.88	0.74	0.48	0.66	0.81	0.41	0.69	0.83	0.53	0.55	-0.18	0.83		0.48	0.84	0.52	0.66	0.66	0.79	0.82	0.81	0.9	0.69	0.65	-0.54	0.79
Common Stock	0.27	0.32	0.41	0.51	0.16	-0.39	0.55	0.59	0.98	0.99	0.54	0.22	0.48		0.2	0.28	0.11	0.08	0.39	0.2	0.19	0.42	0.11	0.1	0.09	0.19
Short Long Term Debt Total	0.99	0.89	0.21	0.29	1.0	0.74	0.57	0.42	0.28	0.26	-0.6	1.0	0.84	0.2		0.77	0.95	0.95	0.8	0.76	0.97	0.73	0.97	0.94	-0.77	0.98
Accounts Payable	0.79	0.86	0.02	0.22	0.75	0.51	0.61	0.15	0.33	0.29	-0.41	0.79	0.52	0.28	0.77		0.85	0.86	0.68	0.32	0.7	0.28	0.83	0.83	-0.51	0.78
Property Plant And Equipment Net	0.94	0.92	0.11	0.17	0.95	0.73	0.48	0.17	0.21	0.16	-0.64	0.96	0.66	0.11	0.95	0.85		0.99	0.72	0.55	0.94	0.51	1.0	1.0	-0.8	0.97
Non Current Assets Total	0.94	0.9	0.07	0.17	0.96	0.79	0.48	0.18	0.18	0.13	-0.69	0.96	0.66	0.08	0.95	0.86	0.99		0.72	0.6	0.92	0.51	0.99	0.99	-0.77	0.96
Non Currrent Assets Other	0.83	0.7	0.5	0.53	0.77	0.5	0.82	0.59	0.45	0.48	-0.32	0.8	0.79	0.39	0.8	0.68	0.72	0.72		0.63	0.76	0.74	0.72	0.68	-0.36	0.81
Other Assets	0.76	0.49	0.14	0.39	0.77	0.65	0.39	0.67	0.24	0.27	-0.5	0.74	0.82	0.2	0.76	0.32	0.55	0.6	0.63		0.68	0.86	0.62	0.55	-0.5	0.66
Inventory	0.96	0.88	0.33	0.28	0.97	0.67	0.49	0.35	0.29	0.26	-0.55	0.97	0.81	0.19	0.97	0.7	0.94	0.92	0.76	0.68		0.73	0.95	0.95	-0.84	0.99
Other Current Assets	0.74	0.51	0.56	0.5	0.72	0.39	0.55	0.76	0.45	0.5	-0.21	0.71	0.9	0.42	0.73	0.28	0.51	0.51	0.74	0.86	0.73		0.56	0.5	-0.45	0.69
Property Plant And Equipment Gross	0.95	0.91	0.1	0.18	0.97	0.76	0.47	0.21	0.21	0.16	-0.66	0.97	0.69	0.11	0.97	0.83	1.0	0.99	0.72	0.62	0.95	0.56		0.99	-0.81	0.98
Property Plant Equipment	0.93	0.92	0.1	0.14	0.95	0.73	0.43	0.15	0.2	0.14	-0.64	0.95	0.65	0.1	0.94	0.83	1.0	0.99	0.68	0.55	0.95	0.5	0.99		-0.84	0.97
Current Deferred Revenue	-0.74	-0.73	-0.06	0.0	-0.8	-0.63	-0.08	-0.08	-0.04	0.06	0.59	-0.77	-0.54	0.09	-0.77	-0.51	-0.8	-0.77	-0.36	-0.5	-0.84	-0.45	-0.81	-0.84		-0.78
Net Receivables	0.97	0.9	0.29	0.29	0.98	0.7	0.56	0.34	0.28	0.25	-0.58	0.98	0.79	0.19	0.98	0.78	0.97	0.96	0.81	0.66	0.99	0.69	0.98	0.97	-0.78

Click cells to compare fundamentals

Halozyme Therapeutics Account Relationship Matchups

Halozyme Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	565.9M	579.9M	1.1B	1.8B	1.7B	1.8B
Other Current Liab	55.6M	20.5M	24.4M	96.5M	99.7M	104.7M
Total Current Liabilities	85.6M	421.4M	117.1M	130.8M	112.5M	67.5M
Total Stockholder Equity	91.8M	151.0M	197.0M	169.8M	83.8M	66.9M
Net Debt	282.4M	249.5M	758.0M	1.3B	1.4B	1.4B
Retained Earnings	(603.7M)	(474.6M)	(58.9M)	143.2M	90.6M	95.1M
Cash	120.2M	147.7M	118.7M	234.2M	118.4M	81.7M
Cash And Short Term Investments	421.3M	368.0M	740.9M	362.8M	336M	196.9M
Common Stock Total Equity	145K	137K	135K	138K	155.3K	104.5K
Common Stock Shares Outstanding	144.3M	141.5M	146.8M	140.6M	134.2M	104.7M
Liabilities And Stockholders Equity	565.9M	579.9M	1.1B	1.8B	1.7B	1.8B
Other Stockholder Equity	695.1M	625.5M	256.3M	27.4M	2.4M	2.3M
Total Liab	474.1M	428.9M	907.5M	1.7B	1.6B	1.7B
Total Current Assets	543.4M	554.8M	926.3M	739.0M	746.4M	783.7M
Common Stock	145K	137K	135K	138K	127K	106.0K
Short Long Term Debt Total	402.6M	397.2M	876.7M	1.5B	1.5B	1.6B
Accounts Payable	6.4M	1.9M	1.5M	17.7M	11.8M	12.4M
Property Plant And Equipment Net	10.9M	10.6M	8.8M	75.6M	74.9M	78.7M
Non Current Assets Total	22.4M	25.2M	178.1M	1.1B	986.8M	1.0B
Non Currrent Assets Other	11.1M	14.1M	13.9M	26.3M	17.8M	9.0M
Other Assets	11.6M	14.6M	169.3M	71.2M	81.9M	86.0M
Inventory	29.4M	60.7M	53.9M	100.1M	127.6M	134.0M
Other Current Assets	33.4M	56.5M	81.0M	45.0M	48.6M	51.0M
Property Plant And Equipment Gross	10.9M	10.6M	21.9M	90.3M	94.6M	99.3M
Accumulated Other Comprehensive Income	240K	22K	(620K)	(922K)	(9.3M)	(8.8M)
Property Plant Equipment	10.9M	10.6M	8.8M	75.6M	86.9M	91.3M
Current Deferred Revenue	4.2M	4.0M	1.7M	3.2M	(32.2M)	(30.6M)
Net Receivables	59.4M	97.7M	91.0M	231.1M	234.2M	245.9M
Other Liab	2.3M	7.5M	3.1M	17.7M	16.0M	26.6M
Non Current Liabilities Total	388.5M	7.5M	790.3M	1.5B	1.5B	1.6B
Net Tangible Assets	90.5M	155.1M	197.0M	(783.7M)	(705.3M)	(670.0M)
Long Term Debt	34.9M	383.0M	787.3M	1.5B	1.5B	1.6B
Retained Earnings Total Equity	(603.7M)	(474.6M)	(58.9M)	143.2M	164.7M	172.9M
Short Term Investments	301.1M	220.3M	622.2M	128.6M	217.6M	203.8M
Capital Surpluse	695.1M	625.5M	256.3M	27.4M	31.5M	29.9M
Long Term Debt Total	34.9M	383.0M	787.3M	1.5B	1.7B	1.8B
Non Current Liabilities Other	4.2M	3.5M	544K	45.9M	37.7M	39.6M
Short Long Term Debt	19.5M	397.2M	89.4M	13.3M	15.3M	14.6M
Short Term Debt	19.5M	378.1M	67.3M	(84.3M)	6.6M	6.3M

Pair Trading with Halozyme Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Halozyme Stock

0.64

ELAN

Elanco Animal Health

Pair Corr

Moving against Halozyme Stock

0.6	EWTX	Edgewise Therapeutics	Pair Corr
0.59	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.58	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.47	GANX	Gain Therapeutics	Pair Corr
0.44	GILD	Gilead Sciences	Pair Corr

The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.

The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock:

How To Invest In Halozyme

Details

Is Halozyme Stock a good investment?

Details

What is Halozyme Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.721

Earnings Share

3.02

Revenue Per Share

7.431

Quarterly Revenue Growth

0.343

Return On Assets

0.1487

The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Halozyme Long Term Debt Total vs Deferred Long Term Liab Analysis

Long Term Debt Total vs Deferred Long Term Liab

Long Term Debt Total vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Long Term Debt Total

Deferred Long Term Liab

Halozyme Therapeutics fundamental ratios Correlations

Halozyme Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Halozyme Therapeutics fundamental ratios Accounts

Pair Trading with Halozyme Therapeutics

Moving together with Halozyme Stock

Moving against Halozyme Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Long Term Debt Total	+ 1.0	Net Debt
Short Long Term Debt Total	+ 1.0	Total Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Total Liab	+ 0.99	Total Assets
Short Long Term Debt Total	+ 0.99	Total Assets

Other Stockholder Equity	- 0.95	Retained Earnings
Current Deferred Revenue	- 0.84	Property Plant Equipment
Current Deferred Revenue	- 0.84	Inventory
Current Deferred Revenue	- 0.81	Property Plant And Equipment Gross
Current Deferred Revenue	- 0.8	Property Plant And Equipment Net
Current Deferred Revenue	- 0.8	Net Debt